+
AstraZeneca India To Sell 64-Acre Bengaluru Facility
Real Estate

AstraZeneca India To Sell 64-Acre Bengaluru Facility

AstraZeneca India is set to divest its 64-acre production facility in North Bengaluru as part of a global reassessment of its manufacturing and supply chain operations. This initiative aligns with the parent company’s broader strategy to optimise resources through corporate land monetization. 

According to the reports in the media, the proposed transaction is estimated to bring in over Rs 32 billion. AstraZeneca has reportedly engaged global property consultants to identify potential buyers for the land, which is valued at more than Rs 500 million per acre. Despite previous attempts to sell, the high valuation had posed challenges in securing a deal. 

The company intends to transfer the facility as a fully operational unit and is actively searching for a buyer who can also serve as a contract manufacturing organization (CMO) to continue its existing production and packaging operations, subject to necessary approvals. 

A key part of AstraZeneca Pharma’s global network, the Bengaluru facility is one of nine sites dedicated to clinical trial design and execution. The planned sale underscores AstraZeneca’s broader strategic shift to streamline global operations while maintaining critical pharmaceutical production through external partnerships. 

AstraZeneca India is set to divest its 64-acre production facility in North Bengaluru as part of a global reassessment of its manufacturing and supply chain operations. This initiative aligns with the parent company’s broader strategy to optimise resources through corporate land monetization. According to the reports in the media, the proposed transaction is estimated to bring in over Rs 32 billion. AstraZeneca has reportedly engaged global property consultants to identify potential buyers for the land, which is valued at more than Rs 500 million per acre. Despite previous attempts to sell, the high valuation had posed challenges in securing a deal. The company intends to transfer the facility as a fully operational unit and is actively searching for a buyer who can also serve as a contract manufacturing organization (CMO) to continue its existing production and packaging operations, subject to necessary approvals. A key part of AstraZeneca Pharma’s global network, the Bengaluru facility is one of nine sites dedicated to clinical trial design and execution. The planned sale underscores AstraZeneca’s broader strategic shift to streamline global operations while maintaining critical pharmaceutical production through external partnerships. 

Next Story
Infrastructure Urban

ABB to Invest Rs 6.25 Billion to Expand India Manufacturing

ABB recently announced plans to invest approximately Rs 6.25 billion ($75 million) in India during 2026 to expand its manufacturing footprint and research and development capabilities. The investment follows more than $35 million spent in 2025 and reflects the company’s continued focus on strengthening its ‘local-for-local’ strategy in the country.The investment will support ABB’s Electrification, Motion and Automation businesses and expand manufacturing capacity for infrastructure sectors such as renewable energy, metro rail, data centres and industrial applications. Approximately 300..

Next Story
Equipment

Six WOLFF Cranes Handle 60,000 m³ Concrete for German Hospital

Six WOLFF tower cranes are playing a key role in constructing a new hospital complex in Memmingen, Germany, supporting large-scale material handling for the project. The facility is being built on a 7.7-hectare site and will feature six floors, around 480 beds and a gross floor area exceeding 75,000 sq m.Building shell works began recently in February 2025. One WOLFF 6531.12 Cross crane supported early site preparation before being dismantled in autumn 2025, while five remaining cranes continue operations. Over an average deployment period of 16 months, the cranes are expected to move approxim..

Next Story
Equipment

REC Funds Rs 115.6 Million CSR Support for Bihar Eye Hospital

REC recently committed Rs 115.6 million under its Corporate Social Responsibility (CSR) programme for the procurement of clinical and non-clinical equipment at Sankara Eye Hospital in Saharsa, Bihar. The initiative aims to strengthen healthcare infrastructure and improve access to specialised eye care services in the region.A Memorandum of Agreement (MoA) was recently signed between Pradeep Fellows, Executive Director (CSR), REC Limited, and Wg Cdr V. Shankar (Retd), Trustee and Executive Director of Sankara Eye Hospital, at the REC office in the SCOPE Complex, New Delhi.The support is expecte..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement